Advisory Alpha LLC Purchases 605 Shares of Eli Lilly and Company $LLY

Advisory Alpha LLC grew its holdings in Eli Lilly and Company (NYSE:LLY) by 13.0% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 5,250 shares of the company’s stock after purchasing an additional 605 shares during the quarter. Advisory Alpha LLC’s holdings in Eli Lilly and Company were worth $4,306,000 at the end of the most recent reporting period.

Other hedge funds have also recently modified their holdings of the company. Vanguard Group Inc. increased its holdings in shares of Eli Lilly and Company by 0.7% in the 3rd quarter. Vanguard Group Inc. now owns 80,959,089 shares of the company’s stock valued at $61,771,785,000 after acquiring an additional 551,659 shares during the period. Laurel Wealth Advisors LLC boosted its position in Eli Lilly and Company by 78,621.2% during the second quarter. Laurel Wealth Advisors LLC now owns 11,552,336 shares of the company’s stock valued at $9,005,392,000 after purchasing an additional 11,537,661 shares in the last quarter. Norges Bank bought a new stake in Eli Lilly and Company during the second quarter valued at about $8,827,714,000. Charles Schwab Investment Management Inc. grew its stake in Eli Lilly and Company by 2.0% in the second quarter. Charles Schwab Investment Management Inc. now owns 5,359,653 shares of the company’s stock valued at $4,178,010,000 after purchasing an additional 103,119 shares during the last quarter. Finally, Franklin Resources Inc. raised its holdings in Eli Lilly and Company by 13.4% in the second quarter. Franklin Resources Inc. now owns 4,766,865 shares of the company’s stock worth $3,715,913,000 after purchasing an additional 564,736 shares in the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Stock Down 0.4%

Eli Lilly and Company stock opened at $1,004.12 on Thursday. The business’s 50-day simple moving average is $1,049.25 and its two-hundred day simple moving average is $936.91. The company has a debt-to-equity ratio of 1.54, a quick ratio of 1.19 and a current ratio of 1.58. The company has a market cap of $947.25 billion, a PE ratio of 43.75, a PEG ratio of 1.17 and a beta of 0.40. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $1,133.95.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Wednesday, February 4th. The company reported $7.54 EPS for the quarter, topping analysts’ consensus estimates of $7.48 by $0.06. The firm had revenue of $19.29 billion during the quarter, compared to the consensus estimate of $17.85 billion. Eli Lilly and Company had a return on equity of 102.94% and a net margin of 31.66%.The company’s revenue was up 42.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $5.32 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. Equities analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Friday, February 13th will be paid a $1.73 dividend. The ex-dividend date is Friday, February 13th. This represents a $6.92 annualized dividend and a dividend yield of 0.7%. This is an increase from Eli Lilly and Company’s previous quarterly dividend of $1.50. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 30.15%.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Shareholders approved Eli Lilly’s acquisition of Ventyx Biosciences, clearing a regulatory/transactional hurdle that extends Lilly’s pipeline and inorganic growth options. Ventyx Merger Approved
• Positive Sentiment: Lilly advanced remternetug (an Alzheimer’s asset) testing in China, broadening its geographic trial footprint and potentially improving future market access in a key region for neurodegenerative therapies. Remternetug China Trial Update
• Positive Sentiment: Lilly progressed a new oral diabetes candidate in China (Phase 1 update), supporting continued expansion of its diabetes/GLP-1 franchise beyond injectable offerings. Pipeline diversification can support longer-term revenue growth. Oral Diabetes Drug in China
• Positive Sentiment: Analyst/market commentary (Zacks) flags Lilly as a strong momentum name and notes elevated investor attention—coverage that can support continued flows and multiple expansion if momentum resumes. Zacks Momentum Coverage
• Neutral Sentiment: The DIA 2026 Global Annual Meeting will bring cross-sector life-sciences attention to product development themes; this is industry-positive but not a direct LLY catalyst. DIA 2026 Meeting
• Neutral Sentiment: Broader market rotation stories (e.g., articles arguing biotech is outperforming AI) could redirect funds into pharma/biotech, a potential tailwind but uncertain for any single name. Biotech vs AI Rotation
• Neutral Sentiment: Competitor/sector updates (e.g., J&J immunology & neuroscience growth) highlight competitive dynamics in immunology/neuroscience but are not an immediate direct hit to Lilly’s headline momentum. JNJ Sector Update
• Negative Sentiment: Valuation and momentum checks note cooling short-term performance after years of strong gains; concerns about stretched multiples are pressuring sentiment and limiting upside near term. Valuation Check
• Negative Sentiment: Some retail/investing commentary recommends reallocating from Lilly into other “unstoppable” stocks, creating narrative-driven outflows and headline risk for momentum investors. Fool: Alternatives to Lilly

Analysts Set New Price Targets

A number of research analysts have recently issued reports on the stock. Rothschild & Co Redburn lifted their price objective on shares of Eli Lilly and Company from $775.00 to $830.00 and gave the stock a “neutral” rating in a research report on Monday, January 26th. TD Cowen raised their target price on shares of Eli Lilly and Company from $960.00 to $1,250.00 and gave the company a “buy” rating in a research note on Thursday, January 29th. Freedom Capital raised shares of Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a report on Tuesday, February 10th. HSBC reaffirmed a “hold” rating and set a $1,070.00 price target on shares of Eli Lilly and Company in a research report on Wednesday, December 10th. Finally, National Bank Financial set a $1,286.00 price objective on Eli Lilly and Company in a report on Monday, December 1st. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and five have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $1,229.59.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.